Product Information
ACETAZOLAMIDE 250 MG TABLET is a generic product labeled by Strides Pharma Inc., priced at $0.1340 per EA under NDC 64380083406. Its NADAC has been published 453 times since Jan 31, 2018.
FDA first approved this application on Nov 20, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380083406
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAZOLAMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA209734FDA Approved
11/20/2017
TE Code
AB
On Market Since
11/20/2017
Pharmacological Classes
Price Statistics
The NADAC for ACETAZOLAMIDE 250 MG TABLET has been published 453 times since Jan 31, 2018, and over the history we have for it it has declined 90.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1340 per EA |
|---|---|
| All-time high | $1.6158 (Mar 14, 2018) |
| All-time low | $0.1231 (Dec 17, 2025) |
| 52-week high | $0.1489 |
| 52-week low | $0.1231 |
| Median price | $0.2518 |
| Average price | $0.5192 |
| Largest weekly change | -52.8% (Aug 18, 2021) |
| Weeks tracked | 453 |
| Tracking since | Jan 31, 2018 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acetazolamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Carbonic Anhydrase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACETAZOLAMIDE 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ACETAZOLAMIDE 250 MG TABLET, manufactured by Strides Pharma Inc., is $0.1340 per EA (NDC 64380083406), effective Sep 30, 2026.
How has the price of ACETAZOLAMIDE 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for ACETAZOLAMIDE 250 MG TABLET has declined 90.7%. It has been tracked across 453 weekly CMS publications since Jan 31, 2018.
What are the highest and lowest recorded NADAC prices for ACETAZOLAMIDE 250 MG TABLET?
Since Jan 31, 2018, the NADAC for ACETAZOLAMIDE 250 MG TABLET has ranged from a low of $0.1231 (Dec 17, 2025) to a high of $1.6158 (Mar 14, 2018), with a median of $0.2518 per EA.
Are there cheaper alternatives to ACETAZOLAMIDE 250 MG TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ACETAZOLAMIDE 250 MG TABLET, is $0.1315 per EA — about 2% below ACETAZOLAMIDE 250 MG TABLET.
Who manufactures ACETAZOLAMIDE 250 MG TABLET?
ACETAZOLAMIDE 250 MG TABLET (NDC 64380083406) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.